NIH-funded research NIH-funded research

Cardiovascular and Kidney Protection with SGLT2 Inhibitors after Kidney Transplant

Official title: Cardiovascular and Renal Protection with SGLT2 Inhibition in Kidney Transplant Recipients (RENAISSANCE)

Funded at University of Minnesota · NIH-11404810 · Data updated 2026-11-12

A study testing whether SGLT2 inhibitors can improve long-term heart and kidney health for adults who have had a kidney transplant.

More Transplant research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Minnesota
NIH-funded
Lab location1 site (Minneapolis, United States)
Project startSeptember 5, 2025
Project endMay 31, 2027
Funding year2026
Award (this year)$352,966
NIH project number5U34DK141987-02
Project IDNIH-11404810 on NIH RePORTER

Who could benefit from this research

Could help

Adults who have received a kidney transplant and are being managed with standard immunosuppression.

Less likely to help

Patients without cardiovascular or kidney risk factors or those unable to tolerate SGLT2 inhibitors may not benefit.

What this research studies

Kidney transplant recipients often live longer than on dialysis, but long-term survival remains a challenge. This project looks at using SGLT2 inhibitors, a class of diabetes drugs, to protect the heart and the transplanted kidney in adults after transplantation. Researchers will assess safety and potential benefits in real-world transplant patients, with careful attention to risks in people who are on immune-suppressing therapy. The study is designed to generate data that could guide future use of these medications to prolong graft function and patient survival. If successful, this work may lead to changes in post-transplant care that improve quality of life for many patients.

Why it matters

Potential benefit: If successful, patients could experience better heart health and longer-lasting kidney function after transplant.

How similar studies have gone: Early data in other kidney disease populations suggest benefits, but this is specifically in transplant recipients and will provide targeted evidence.

Where this research is happening

  • University of Minnesota
    Minneapolis, United States
    Active

Researchers

  • Principal investigator: Matas, Arthur J — University of Minnesota
  • Study coordinator: Matas, Arthur J

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.